Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Gross Margin: 2020-2025

Historic Gross Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to 100.00%.

  • Mereo BioPharma Group's Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year decrease of 455000.00%. This contributed to the annual value of 100.00% for FY2024, which is 2574.00% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Gross Margin of 100.00% as of Q3 2025, which was down 0.00% from 100.00% recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Gross Margin high stood at 127.30% for Q4 2023, and its period low was 61.89% during Q2 2023.
  • Moreover, its 3-year median value for Gross Margin was 100.00% (2025), whereas its average is 99.02%.
  • As far as peak fluctuations go, Mereo BioPharma Group's Gross Margin slumped by 3,811bps in 2023, and later skyrocketed by 3,811bps in 2024.
  • Over the past 5 years, Mereo BioPharma Group's Gross Margin (Quarterly) stood at 100.00% in 2021, then remained steady at 100.00% in 2022, then plummeted by 3,811bps to 127.30% in 2023, then crashed by 2,730bps to 100.00% in 2024, then remained steady at 100.00% in 2025.
  • Its last three reported values are 100.00% in Q3 2025, 100.00% for Q2 2025, and 100.00% during Q1 2025.